Shares of MiMedx Group, Inc. (NASDAQ:MDXG) were up 6.3% during trading on Monday . The stock traded as high as $7.48 and last traded at $7.41. Approximately 2,953,807 shares traded hands during trading, a decline of 10% from the average daily volume of 3,290,797 shares. The stock had previously closed at $6.97.
Several analysts have commented on MDXG shares. BidaskClub downgraded MiMedx Group from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Craig Hallum reiterated a “buy” rating on shares of MiMedx Group in a research note on Tuesday, February 27th. Needham & Company LLC downgraded MiMedx Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Lake Street Capital downgraded MiMedx Group from a “buy” rating to a “hold” rating and set a $9.00 target price on the stock. in a research note on Friday, February 23rd. Finally, ValuEngine downgraded MiMedx Group from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. MiMedx Group has an average rating of “Hold” and an average target price of $14.75.
The company has a market cap of $773.91, a P/E ratio of 61.75, a price-to-earnings-growth ratio of 0.91 and a beta of 1.61.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://weekherald.com/2018/04/16/mimedx-group-mdxg-trading-up-6-3.html.
MiMedx Group Company Profile
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.